Latest insights

Insights from our Founder's blog, relevant podcasts and a deeper dive with our scientific communications.

Founder's blog

26 March 2026

Welcome to the Angiex Founder's Blog

Welcome to the Angiex Founder's Blog

Read more

Videos

07 January 2025

Angiex kicked off 2025 with an appearance on Twinning Strategy.

In this episode of Twinning Strategy, Angiex CEO Paul Jaminet discusses the development of AGX101, a TM4SF1-directed antibody-drug conjugate (ADC) designed to target tumor cells and their blood supply.

Read more

31 October 2024

An inside look at Angiex’s development of AGX101

Watch Angiex CEO Dr. Paul Jaminet and founder Dr. Harold Dvorak, a leading authority on angiogenesis, present at a Force Family Office webinar. This engaging session offers an inside look at Angiex’s development of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) designed to target both tumor cells and the blood vessels that feed them

Read more

20 September 2024

Angiex CEO presents on AGX101’s groundbreaking mechanism of action

Join Angiex CEO Dr. Paul Jaminet as he presents at the MedInvest 2024 October Meeting, offering a comprehensive overview of AGX101, the company’s first-in-class TM4SF1-directed antibody-drug conjugate (ADC).

Read more

Scientific communications

17 November 2024

Angiex presents preclinical data at AACR Special Conference in Cancer Research

Taking place November 17-20, 2024 in Boston, Massachusetts, will feature a poster presentation by Angiex, titled “AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial.”

Read more

07 May 2024

Angiex founder publishes paper describing the TM4SF1 intracellular transport pathway utilized by AGX101

Angiex founder publishes paper describing the TM4SF1 intracellular transport pathway utilized by AGX101

Read more

Contact us

Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...